Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.
This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
